Mark J. Ratain to Drug Therapy, Combination
This is a "connection" page, showing publications Mark J. Ratain has written about Drug Therapy, Combination.
Connection Strength
0.270
-
Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew. Clin Pharmacol Ther. 2019 09; 106(3):498-500.
Score: 0.142
-
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8.
Score: 0.044
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.034
-
Rationale for phase I study of UFT plus leucovorin and oral JM-216. Oncology (Williston Park). 1997 Sep; 11(9 Suppl 10):26-9.
Score: 0.032
-
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
Score: 0.013
-
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
Score: 0.005